Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36% chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.

Original languageEnglish (US)
Pages (from-to)386-390
Number of pages5
JournalJournal of NeuroVirology
Volume7
Issue number4
DOIs
StatePublished - Oct 4 2001

Fingerprint

Progressive Multifocal Leukoencephalopathy
Cytarabine
Therapeutics
Pancytopenia
Neurologic Examination
Activities of Daily Living
Neurologic Manifestations
Nervous System Diseases
Nervous System
Bone Marrow
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Biopsy
Polymerase Chain Reaction
Brain

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. / Aksamit, Allen Jr.

In: Journal of NeuroVirology, Vol. 7, No. 4, 04.10.2001, p. 386-390.

Research output: Contribution to journalArticle

@article{e271ae749a7f419fa62041a20279819f,
title = "Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside",
abstract = "This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36{\%} chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.",
author = "Aksamit, {Allen Jr.}",
year = "2001",
month = "10",
day = "4",
doi = "10.1080/13550280152537292",
language = "English (US)",
volume = "7",
pages = "386--390",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

AU - Aksamit, Allen Jr.

PY - 2001/10/4

Y1 - 2001/10/4

N2 - This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36% chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.

AB - This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36% chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.

UR - http://www.scopus.com/inward/record.url?scp=0034827241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034827241&partnerID=8YFLogxK

U2 - 10.1080/13550280152537292

DO - 10.1080/13550280152537292

M3 - Article

C2 - 11517422

AN - SCOPUS:0034827241

VL - 7

SP - 386

EP - 390

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 4

ER -